Bee Pollen, Propolis, Royal Jelly — Beyond Honey

დანამატები · §486

Bee pollen, propolis, royal jelly: three jars beyond the honey that the wellness aisle sells as immune boosters and antioxidant bombs. The biology is real — concentrated plant polyphenols, the same family that makes berries and green tea worth eating — but the trial evidence is much narrower than the marketing. A modest case for propolis lowering blood sugar in people with type-2 diabetes; thinner cases for royal jelly on lipid markers and bee pollen on basically anything; and no randomised data at all for the "immune support" the labels lead with. The rare downside is the line nobody markets: anaphylaxis on first oral exposure, especially to royal jelly in people with asthma, has killed people.

იცოდე · საჭიროებისამებრ მტკიცებულება შერეული თავი დანამატები

None of the three jars quite earns the price the marketing implies. The honest summary: a modestly effective propolis case for mild blood-sugar trouble in a motivated user willing to source a characterised product; a thinner case for royal jelly on lipids; an even thinner case for bee pollen on anything in healthy adults; and a real allergy hazard across all three. If you're spending $100–200 a year on these for "immunity," that money buys more elsewhere.

Bee pollen is the pellet a forager carries back on her legs — flower pollen packed with a little nectar and bee enzymes. It runs about 20–30% protein and carries a flavonoid load (quercetin, kaempferol, rutin) comparable to good fruit Khalifa et al. 2021.

Propolis is the resin bees scrape off tree buds and use to caulk the hive. The active fraction is a mix of flavonoids and phenolic acid esters — caffeic acid phenethyl ester (CAPE) in temperate-zone propolis, artepillin C in Brazilian green propolis — and the polyphenol content varies by an order of magnitude between products carrying the same word on the front Anjum et al. 2019.

Royal jelly is the glandular secretion nurse bees feed the queen. The active ingredient on the label is 10-HDA (10-hydroxy-2-decenoic acid), a fatty acid that runs 1–6% of dry weight in a real product and is essentially absent from a heavily diluted one Pasupuleti et al. 2017.

Three biologically different things sharing one shelf. The shared throughline is the polyphenol load — the same family of compounds that earns berries, olive oil, and green tea their reputation.

What the trials actually show

Propolis has the strongest claim — narrow, but it clears the bar. In adults with type-2 diabetes, eight to twelve weeks of standardised propolis at 900 to 1500 mg a day lowers fasting blood sugar by about 14 mg/dL and HbA_1c by roughly half a percentage point. That's a real biomarker shift — about half of what metformin does, the standard first-line drug, but large enough to matter to someone working a borderline number.

Royal jelly shifts lipid markers in small studies — about a 7.7% drop in LDL cholesterol in a four-week trial of fifteen volunteers given 6 g a day Guo et al. 2007, with modest blood-sugar effects in a separate trial of diabetic women on 1 g a day Pourmoradian et al. 2014. The trials are short, often small, and product-specific. Bee pollen is the thinnest of the three: antioxidant biomarkers move in lab tests, some menopausal-symptom data is confined to one proprietary extract, and no large healthy-adult trial of any marketed claim exists Khalifa et al. 2021.

The antioxidant story across all three is mostly biomarker work — plasma antioxidant capacity goes up, lipid-peroxidation markers come down Afsharpour et al. 2019. Whether that shows up as anything you'd notice in your fifties is the same question that hangs over every polyphenol-rich food, and the same answer: probably yes, probably small, probably not the lever that decides the trajectory.

The immune claim — the marketing centrepiece — is where the literature collapses hardest. No randomised trial has shown that ingested bee products reduce the number of colds or flus a healthy adult catches in a year. Biomarker work on CRP and IL-6 shows mixed, often small, often null effects Pasupuleti et al. 2017. The jump from there to "supports immunity" is marketing, not data.

The jar on the shelf is not the jar in the trial

The biggest misconception in this category isn't does it work. It's this jar is that jar. It isn't.

Brazilian green propolis, with its artepillin C, is biochemically different from European poplar propolis, which is mostly CAPE and pinocembrin Anjum et al. 2019. Bee pollen composition varies by whatever the foragers fed on that month — clover meadow, pine forest, urban park, lavender field — and the label cannot tell you which. Royal jelly's standardisation marker, 10-HDA, is rarely reported on US labels at all; the EU permits some claims at a 1.4% floor, but enforcement is patchy Pasupuleti et al. 2017.

This is not a small detail. Every cited trial used a specific characterised preparation, supplied by an investigator who knew what was in it. The Iranian propolis at 1500 mg/day that dropped HbA_1c isn't being sold under that name in your local store. Reproducing the dose with a different brand isn't reproducing the trial; it's running an uncontrolled experiment on yourself.

The second misconception is the immune-booster framing. Bees use propolis to seal the hive against microbes is true, and tells you almost nothing about what ingested propolis does at supplement doses inside a human body. The immune system isn't a tank that fills up with antioxidants. The phrase works because most readers don't picture what's actually being claimed.

The allergy risk is real and underspoken

The least-marketed line in this category is also the most important. Royal jelly has been implicated in asthma flares and anaphylaxis, including a documented fatal case in an asthmatic woman in Australia Thien et al. 1996. Community data from Hong Kong put royal-jelly-induced anaphylaxis at roughly 0.15% of consumers — rare, but the consequences are catastrophic, and the risk runs sharply higher in atopic and asthmatic individuals Leung et al. 1997. Bee pollen has its own case literature of severe reactions on first oral exposure, particularly in people with seasonal pollen allergies Cohen et al. 1979. Propolis allergy usually shows up as contact dermatitis — propolis ranks among the more frequent positive results in dermatology patch-test series Sforcin 2016 — but oral exposure can produce mucosal reactions.

If you're on a blood thinner or an antiplatelet, talk to whoever prescribes it before adding propolis — propolis flavonoids inhibit platelet aggregation in lab work, and clinical bleeding has been reported. Pregnancy and lactation default to avoidance for royal jelly, where reproductive-effect data is too thin to offer reassurance.

If you're going to try one anyway

Two operational moves. The first is deciding which product, which is the same as deciding what you're actually trying to do. Propolis for a mild fasting-glucose number you're working on with your GP, after an atopy-free history. Pass on the others until the evidence catches up; royal jelly and bee pollen as general-wellness jars are mostly buying the label.

The second is reading the label for a number, not an adjective. For propolis, look for a stated polyphenol content in milligrams of gallic acid equivalent per dose, or — for Brazilian green propolis — a stated artepillin C content. For royal jelly, look for the 10-HDA percentage; fresh royal jelly on the label means it has to be refrigerated. For bee pollen, the floral source if disclosed, and a recent harvest date. Most retail products carry none of this, which is the standardisation problem made operational: you don't know what you bought, and the trial author wouldn't recognise it as the substance they studied.

Annualised costs at typical use, in 2024–2026 markets: bee pollen at a teaspoon a day runs $20–60 a year; propolis tincture or capsules at 500 to 1500 mg a day run $40–120; standardised high-10-HDA royal jelly runs $80–250. Royal jelly is the most expensive per gram and the most marketing-driven.

What the money would do somewhere else

At $100–200 a year for the cabinet — a thousand-plus dollars across a decade — the comparison isn't is the polyphenol load worth it. The comparison is what that money does pointed at the things with real effect sizes. A year of a gym membership held instead of cancelled in March. The dental cleaning you keep rescheduling. The pair of running shoes that gets you outside three more times a week. A metformin or statin conversation with your GP that costs nothing and runs an effect an order of magnitude larger than any jar on the bee shelf.

The Sunday-night moment of opening the cabinet and seeing the half-finished royal jelly bottle — the one you couldn't tell whether it did anything — that quiet recurring shame about another wellness purchase: it stops accumulating, once you've decided.

Topical propolis is a separate conversation — wound dressings, mouthwashes, aphthous-ulcer gels — with its own evidence base and dose-response. Manuka honey for burn and wound care sits in the same neighbourhood. Apitherapy in the bee-venom sense is a different domain again, with weaker evidence. And the underlying polyphenol-intake question, which most of the antioxidant claim here actually reduces to, is well-served by olive oil, berries, green tea, and the rest of the Mediterranean dietary pattern — none of which carry the allergy hazard.

1. Substance + claimed effects

"Bee products beyond honey" refers to three supplemental foods harvested from the hive but compositionally and biologically distinct from honey: bee pollen (floral pollen grains compacted by foragers with nectar and salivary enzymes, sold as granules or capsules), propolis (a resinous mix of plant exudates and bee secretions used to seal and antiseptically coat the hive, sold as tinctures, capsules, or lozenges), and royal jelly (a pharyngeal-gland secretion of nurse bees, used to feed larvae and the queen, sold as fresh paste, freeze-dried capsules, or lyophilised powder) Pasupuleti et al. 2017. Their proximate compositions differ: bee pollen runs 20–30% protein with 13–55% carbohydrate and a broad polyphenol fraction (1.6% by dry weight, dominated by quercetin, kaempferol, rutin) Khalifa et al. 2021; propolis is mostly resin and wax with the bioactive fraction concentrated in flavonoids (pinocembrin, galangin, chrysin) and phenolic acid esters (CAPE, artepillin C in Brazilian green propolis) Anjum et al. 2019 Sforcin 2016; royal jelly is ~60–70% water with major royal jelly proteins (MRJPs) and a marker lipid 10-hydroxy-2-decenoic acid (10-HDA) typically at 1–6% of dry weight Pasupuleti et al. 2017. Claimed consequences in the marketing and trial literature cluster around antioxidant and immune markers (all three), glycemic and lipid markers (propolis strongest, royal jelly secondary), wound-healing and oral-mucosal applications (propolis only — out of scope here, which covers oral ingestion), athletic performance and menopause symptoms (bee pollen and royal jelly), with two cross-cutting concerns the brief flags: allergic and sensitization risk, and the standardization ceiling on every product class. The entry covers all of these holistically — the same substance class generating each effect — and lands on a low-to-moderate evidence rating overall.

2. Evidence by addressing question

Mechanism

Polyphenol fraction. The shared throughline across the three products is a polyphenol load comparable to high-flavonoid plant foods. Bee pollen flavonoids (quercetin, kaempferol, rutin, isorhamnetin) inhibit lipid peroxidation in vitro at physiological concentrations and quench DPPH radicals dose-dependently Khalifa et al. 2021. Propolis flavonoids and CAPE (caffeic acid phenethyl ester) suppress NF-κB signalling in cultured macrophages, reduce iNOS / COX-2 expression, and inhibit TNF-α release Sforcin 2016 Anjum et al. 2019. Royal jelly's 10-HDA has documented antimicrobial activity and modest oestrogen-receptor binding affinity in vitro that plausibly underwrites menopause-symptom claims, though human dose-response is unestablished Pasupuleti et al. 2017.

Protein and peptide fractions. Bee pollen carries all essential amino acids and contributes a complete-protein source by weight, though the daily-use dose (1–3 tablespoons, ~10–30 g) makes its absolute protein contribution small relative to ordinary food Khalifa et al. 2021. Royal jelly MRJPs (especially MRJP1, royalactin) are biologically active in larval bee development; in adult humans the proteins are mostly digested and the systemic activity claimed by marketing is speculative Pasupuleti et al. 2017. Propolis contributes minimal protein.

Antimicrobial activity. Strongest for propolis: well-characterised in vitro inhibition of Gram-positive bacteria, some Gram-negative species, several fungi and enveloped viruses, mediated through membrane disruption and ATPase inhibition Sforcin 2016. This is the basis for topical and oral-mucosal applications (out of scope here); whether ingested systemic propolis reaches blood concentrations relevant for systemic antimicrobial activity is unclear.

Evidence

Glycemic markers — propolis (the strongest claim). A double-blind RCT in 66 patients with T2DM (Iranian propolis 1500 mg/day for 8 weeks vs placebo) showed significant reductions in fasting glucose (−14.5 mg/dL) and HbA_1c (−0.55%) versus placebo Zakerkish et al. 2019. A second double-blind RCT (Iranian propolis 900 mg/day, 12 weeks, n=62 T2DM) showed similar reductions in fasting glucose and HbA_1c alongside improved superoxide dismutase activity Afsharpour et al. 2019. A 2019 meta-analysis pooling seven RCTs concluded propolis lowers fasting glucose (weighted mean difference −13.51 mg/dL, 95% CI −22.27 to −4.75) and HbA_1c (WMD −0.52%, 95% CI −0.91 to −0.13) in T2DM, but flagged heterogeneity in propolis source, dose, and treatment duration Karimian et al. 2019. Effect size is real but smaller than first-line metformin (~1% HbA_1c reduction); positioning is as a possible adjunct in mild dysglycemia, not a substitute.

Lipid markers — royal jelly and propolis (modest, mixed). A 4-week RCT in 15 healthy volunteers given royal jelly 6 g/day showed reduced LDL cholesterol (−7.7%) and total cholesterol versus baseline, with no change in HDL Guo et al. 2007. The Pourmoradian 2014 RCT in 50 T2DM women (royal jelly 1 g/day, 8 weeks) showed reductions in fasting glucose and HbA_1c but lipid effects were limited Pourmoradian et al. 2014. Propolis trials in T2DM also report modest LDL reductions inconsistently across studies Afsharpour et al. 2019. The overall lipid signal is small and trial-quality-dependent.

Antioxidant markers. Most RCTs across all three products report improvements in plasma antioxidant capacity (FRAP, TAC) and reductions in malondialdehyde (a lipid-peroxidation marker) over 4–12-week supplementation Afsharpour et al. 2019 Pourmoradian et al. 2014. These are biomarker shifts; whether they translate to clinically meaningful disease prevention is unestablished — the same critique that applies to most polyphenol-rich foods.

Immune markers. Trials report variable changes in CRP, IL-6, and TNF-α — mostly small, often not consistent across studies, occasionally null Zakerkish et al. 2019 Pasupuleti et al. 2017. The "immune booster" marketing claim outruns the data substantially: no large RCT has demonstrated reduced incidence of common infections from ingested bee products in healthy adults.

Glycemic markers — royal jelly secondary. Münstedt 2009 reported a small reduction in 2-hour glucose tolerance in 20 healthy subjects given 20 g royal jelly Münstedt et al. 2009. Pourmoradian 2014 (above) replicated the glycemic signal in T2DM women.

Bee pollen — the thinnest evidence base. Bee pollen has fewer human RCTs than propolis or royal jelly. Small trials report antioxidant biomarker improvements and modest effects on menopausal vasomotor symptoms in pollen-extract preparations (Femal); mechanism plausibility is high but pivotal trials in healthy adults are absent Khalifa et al. 2021.

Contraindications

Allergic reactions are the most clinically important contraindication for all three products. Royal jelly is the most documented hazard: Thien et al. described asthma and anaphylaxis induced by royal jelly in atopic patients, including a fatal case in an asthmatic woman Thien et al. 1996. Australian and Hong Kong epidemiology data place royal-jelly-induced anaphylaxis at roughly 0.15% community prevalence among consumers, with substantially higher risk in those with atopy or asthma Leung et al. 1997. Bee pollen anaphylaxis has been reported repeatedly in case literature, including severe reactions on first exposure in patients with seasonal pollen allergies Cohen et al. 1979. Propolis allergy is primarily contact dermatitis rather than systemic anaphylaxis — propolis is among the more common positive results on patch-testing in dermatology series, particularly in dental and apicultural workers — but oral exposure can produce mucosal reactions Sforcin 2016. Cross-reactivity with bee venom is partial and inconsistent; a clean bee-sting history does not rule out a reaction to ingested bee products. Additional cautions: blood thinners (propolis flavonoids inhibit platelet aggregation in vitro), pregnancy (insufficient data on royal jelly's reproductive effects), and asthmatic patients (royal jelly is contraindicated in clinical practice in Australia after Thien 1996).

Misconceptions

"Natural means standardized." The central misconception is that products with the same label name (bee pollen, propolis, royal jelly) carry comparable activity. They don't. Brazilian green propolis (Baccharis source, rich in artepillin C) is compositionally distinct from European poplar propolis (rich in pinocembrin and CAPE) and Russian propolis (birch-source). Polyphenol content varies an order of magnitude across products of nominally the same type Anjum et al. 2019. Bee pollen composition varies by foraged flora — pollen from a beekeeper running in a clover meadow vs a pine forest vs an urban park is biochemically different, and the label cannot tell you which you bought Khalifa et al. 2021. Royal jelly's standardisation marker, 10-HDA, is rarely reported on US/EU labels; the EU permits a 1.4% 10-HDA floor for some claims but enforcement is patchy Pasupuleti et al. 2017. The trial showing an effect from "propolis 1500 mg" was using a specific Iranian propolis extract characterised by the investigators; readers reproducing the dose with a different product are not reproducing the trial.

"Immune booster" rhetoric. The marketing language ("strengthens the immune system") implies a directional benefit that the data does not support. Immune biomarker shifts in trials are mixed — CRP and IL-6 sometimes drop, sometimes don't Pasupuleti et al. 2017. No RCT has shown reduced incidence of common infections (URI, influenza) in healthy adults supplementing with ingested bee products. The mechanism literature supports a modulatory rather than tonic effect.

"If bees use it, it must be powerful." The fact that propolis seals the hive against microbes (and does so well) is a mechanism observation about topical use in a specific environment; it does not predict that ingested propolis at typical supplement doses reaches anti-infective concentrations in human plasma.

Practicalities

Cost in 2024–2026 markets: bee pollen runs $20–60/year at typical 1-tsp/day doses; propolis tincture or capsules run $40–120/year at typical 500–1500 mg/day doses; royal jelly is the most expensive, with high-10-HDA standardised products running $80–250/year. Storage requirements differ: fresh royal jelly requires refrigeration and degrades within months; lyophilised royal jelly is stable for ~2 years; propolis tinctures are alcohol-stabilised and shelf-stable; bee pollen requires cool, dry storage and degrades over months at room temperature. Label evaluation: for propolis, look for a stated polyphenol content (mg gallic acid equivalent per dose) or, for Brazilian green propolis, a stated artepillin C content; for royal jelly, look for a stated 10-HDA percentage; for bee pollen, the floral source if disclosed. Most retail products do not carry these specifications, which is the standardisation problem made operational.

Stakes

The reader's downside from including these products at typical doses, in the absence of an allergic reaction, is primarily financial — $50–250/year for effects that are modest where they exist (propolis glycemic effects in T2DM) and undemonstrated where they're most heavily marketed (immune support in healthy adults). The non-financial downside is opportunity cost: the same attention and budget directed at first-line dietary or pharmacologic interventions (Mediterranean dietary pattern, metformin for prediabetes, a statin where indicated) carries substantially larger and better-established effect sizes. The catastrophic downside, low-probability but high-consequence, is anaphylaxis on first exposure in an undiagnosed atopic — most relevant to royal jelly and bee pollen.

Misconceptions / Failure modes overlap

The common failure mode is reading a single positive trial (a propolis-and-T2DM RCT, say) and inferring the effect generalises to (a) other propolis products, (b) non-diabetic users, (c) the marketed "immune" outcome rather than the trialled biomarker. Each of these inferences is unsupported. The second failure mode is delaying conventional care for a clinically actionable condition (uncontrolled T2DM, hypercholesterolemia) while trialling bee products for months.

Out of scope

Topical propolis applications (wound healing, dental gels, aphthous ulcer treatment, oral-mucosal lozenges) — different bioavailability profile, different evidence base, plausibly its own entry. Honey itself — separate entry. Manuka honey's wound-care applications — also separate. Apitherapy (bee-venom therapy, hive-air therapy) — separate domain, low-quality evidence. Beekeeping as a hobby or livelihood — not a Body Handbook topic.

3. The credibility range

Optimist case

Three distinct natural products with thousands of years of traditional use across cultures, each carrying a coherent polyphenol-rich biochemistry with documented antioxidant and modulatory activity. Modern RCTs — most notably the propolis T2DM literature with consistent fasting-glucose and HbA_1c reductions across multiple double-blind trials and a positive meta-analysis Karimian et al. 2019 — validate at least one specific use case at trial-derived doses. Royal jelly's lipid signal is small but replicated. The standardisation problem is solvable through better labelling (10-HDA, artepillin C, polyphenol equivalents), not a fundamental obstacle. For a motivated user willing to pay for a characterised product, the propolis-for-mild-dysglycemia case clears the bar; the antioxidant biomarker shifts across all three products are mechanistically coherent. Where the marketing overreaches the data, that is a marketing problem; the underlying biology and trials are real.

Skeptic case

The propolis T2DM literature is dominated by Iranian RCTs of moderate methodological quality with the same propolis source and overlapping investigator networks; geographic and source-product narrowing limits external validity. Effect sizes (0.5% HbA_1c reduction) are smaller than metformin and the trials are short (8–12 weeks). The bee pollen literature is mostly mechanism and small-trial biomarker shifts; the menopause data is limited to a proprietary extract (Femal) and does not generalise to retail bee pollen. The royal jelly lipid signal rests on small studies, often without placebo controls; the Guo 2007 design was open-label. Across all three products, every cited study uses a specific characterised preparation, and retail products bear no enforced relationship to those preparations. The allergic risk is real and includes documented fatalities (royal jelly in asthmatics). The opportunity-cost case is severe: a user committed to evidence-based supplementation has dozens of higher-evidence options for any given dimension (statins or lipid-lowering diet for LDL; metformin or low-carb dietary patterns for glycemic; established polyphenol food sources like olive oil, berries, green tea for antioxidant intake) at lower cost and higher reliability. The honest summary is: a class of expensive, poorly standardised supplements with modest, narrow evidence and a non-trivial allergy hazard.

Author's call

The entry lands closer to skeptic than optimist, but not dismissively. Propolis has the cleanest claim — mild dysglycemia in a motivated, atopy-screened user willing to source a characterised product — and that claim is real, just smaller than the marketing implies. Royal jelly and bee pollen sit at "plausible mechanism, thin trial evidence, real allergy risk" — interesting but not recommended interventions. The dominant editorial move is the standardisation point: the same word on the label maps to wildly different products, and most retail labels carry no characterisation that lets the reader replicate the trial doses. evidence at 2 (sparse and product-dependent, mechanism plausible); controversy at 2 (debate is about how much weight to give modest trials with standardisation problems, not a battleground); overall meta lean is "know enough to skip the hype" rather than "do this".

4. Stakeholder + incentive map

Commercial — supplement manufacturers and apicultural cooperatives. Bee products are high-margin niche supplements with a strong "natural" / "ancestral" marketing pull. Brazilian green propolis is a particular commercial category with sustained R&D investment from cooperatives. Royal jelly is the most expensive per gram and the most marketing-driven.
Cultural — traditional medicine, naturopathy, wellness influencers. Bee products carry centuries of folk use (Egyptian, Chinese, Russian apitherapy traditions). Wellness influencers cluster claims around the "immune boost" axis, which the data does not support at the strength claimed.
Regulatory — EU EFSA and national agencies. EU permits limited health claims on royal jelly with a 10-HDA marker; US FDA treats all three as dietary supplements without disease-claim authorisation. Enforcement of marker content on labels is patchy.
Counter — allergy/asthma clinical community. Pulmonologists and allergists in Australia (where Thien 1996 originated) actively discourage royal jelly use in asthmatics; the warning is less visible in US/EU clinical practice.
Academic — apitherapy research networks. A cohesive but small global research community (Brazil, Iran, Japan, China, Turkey) generates most of the human-trial literature. Productive, but small-network risk: positive-result clustering, source-product narrowing, limited independent replication outside the network.

5. Population variability

Atopic individuals and asthmatics. Substantially elevated risk of allergic reactions, including anaphylaxis, to all three products. Royal jelly is specifically contraindicated in asthma in Australian clinical practice. Patients with seasonal pollen allergies should not assume bee-pollen ingestion is safe — case-reports include severe reactions on first oral exposure.
People with T2DM or prediabetes. The strongest direct evidence base (propolis glycemic effect) applies here; effect size remains smaller than first-line therapy.
Patients on blood thinners (warfarin, DOACs, antiplatelets). Propolis flavonoids inhibit platelet aggregation in vitro; clinical bleeding has been reported in case literature. Avoid or discuss with prescribing clinician.
Pregnancy and lactation. Insufficient safety data on royal jelly's reproductive effects; default to avoidance.
Menopausal women. Some data (proprietary bee-pollen extract, royal jelly) for vasomotor symptoms; doesn't generalise to retail products.
Bee-product workers (apiculturists, processors). Elevated baseline sensitisation rates from occupational exposure complicate interpretation of community allergy rates.

6. Knowledge gaps

No large, multi-site, multi-country RCTs of any of the three products with standardised characterisation against placebo on a clinical (not biomarker) endpoint.
No trials in healthy adults with the marketed "immune support" outcome (URI / influenza incidence).
No dose-response curves for ingested propolis flavonoid intake that would let a reader translate a label's mg polyphenol equivalent into an expected glycemic or lipid effect.
No reliable post-marketing surveillance of allergic reactions to retail bee products in any major market; incidence is inferred from case literature.
What evidence would change the author's call: a multi-site Phase III RCT with a characterised, label-standardised product on a clinical endpoint; or post-marketing surveillance numbers low enough to retire the allergy concern (which is unlikely given case literature).

Entry lands skeptic-leaning with the propolis-for-T2DM case carved out as the one real claim. The lever throughout is relief / not-being-conned; meta score is low (~9 overall), so the dream narrative was optional but written anyway because the relief lever is the honest hook here.

Coverage relative to brief: the brief named four consequence areas (antioxidant/immune markers, lipid markers, allergy/sensitization risk, evidence quality and standardisation). All four are covered end-to-end — antioxidant and immune in evidence; lipid in evidence; allergy in contraindications with a dedicated warning callout; standardisation as the structural argument of misconceptions and the operational instruction in practicalities. No silent narrowing.

Hard scoping calls:

Topical propolis excluded. Wound care, mouthwash, aphthous-ulcer gels have a different bioavailability profile and a separate (mostly more positive) evidence base. Folded into out-of-scope as a future-entry candidate. The decision keeps this entry on the "ingested supplemental food" framing the brief asked for.
Manuka honey not included. Belongs with honey/topical wound care, not here.
Bee-venom apitherapy not included. Different domain, weaker evidence, would dilute scope.
Athletic-performance claims for bee pollen mentioned but not foregrounded. Trials are small and inconsistent; not a load-bearing claim.

Rating difficulties:

evidence = 2. Tempting to score 3 on the strength of the propolis-T2DM meta-analysis (Karimian et al. 2019), but the source-product heterogeneity across the pooled RCTs and the Iranian-network concentration of investigators argue against. Held at 2.
health_short_term = 1. The propolis glycemic effect is real and clinical, but small and confined to T2DM; healthy adults don't feel anything across these products. Holistically, a 1.
beauty_cumulative = 1. Scored on the polyphenol/antioxidant-intake throughline shared with green tea, berries, olive oil — barely earns a 1 rather than a 0, but consistent with how those other polyphenol-rich foods are scored.
cost_burden = 2. Could justify 1 for users only buying bee pollen ($20–60/yr), but the realistic basket (pollen + propolis + royal jelly, which is how marketing pushes them) sits in the $50–500 band.
Asthma not in the contraindications closed vocabulary. The specific royal-jelly-in-asthma warning is the single most clinically important contraindication in this entry; it lives in the warning callout, not the metadata field. Worth flagging that the closed vocabulary doesn't carry asthma.

Separate-entry candidates: Topical propolis for wound and oral mucosa; Manuka honey for burns; Bee venom and apitherapy; possibly Standardisation problems in herbal and natural-product supplements as a general piece.

Future-link candidates: this entry should cross-link, once they exist, to entries on the Mediterranean dietary pattern, green tea polyphenols, metformin for prediabetes, statin decisions, and the general "natural supplement standardisation" piece.